Toby Smith has spent in the confectionery and food industry, most of that time with one of the world’s largest supermarket ...

Eli Greenblat has written for The Age, Sydney Morning Herald and Australian Financial Review covering a range of sectors across the economy and stockmarket. He has covered corporate rounds such as ...

Eli Greenblat has written for The Age, Sydney Morning Herald and Australian Financial Review covering a range of sectors across the economy and stockmarket. He has covered corporate rounds such as ...

The US Government has placed a controversial copper mine proposed by Rio Tinto and BHP on its Fast-Track approvals list. ...

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now. The GLP-1 agonist opportunity is gearing up for its next ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

The most recent trading session ended with Eli Lilly (LLY) standing at $827.54, reflecting a +1.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 2.51%.

Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight ...

Coles has edged slightly ahead of Woolworths as the preferred supermarket for Australians as it ramps up pressure on its arch ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...